Shenzhen Neptunus Interlong Bio-technique Company Limited provided consolidated earnings guidance for the year ended 31 December 2023. For the period, the group is expected to record a decrease of more than 50% in the profit attributable to the owners of the company for the year ended 31 December 2023 as compared to the corresponding period in 2022. The decrease was mainly due to the loss of provision for impairment of goodwill incurred by the Group in the acquisition of Beijing Neptunus Zhongxin Pharmaceutical Co., Limited.
Shenzhen Neptunus Interlong Bio-technique Company Limited
Equities
8329
CNE100000775
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 HKD | +4.17% | -3.23% | -8.54% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.54% | 30.88M | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- 8329 Stock
- News Shenzhen Neptunus Interlong Bio-technique Company Limited
- Shenzhen Neptunus Interlong Bio-Technique Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023